AVIR Q1 2021 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M

Gross Profit

$39M59.7% margin

Operating Income

$31M46.5% margin

Net Income

$31M46.5% margin

EPS (Diluted)

$0.34

QoQ Revenue Growth

+35.7%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$841M

Total Liabilities

$254M

Stockholders' Equity

$586M

Cash & Equivalents

$834M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$0	—
Gross Profit	$39M	-$4,000	+985450.0%
Operating Income	$31M	-$4M	+857.8%
Net Income	$31M	-$4M	+870.1%